Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin
|
|
- Tiffany Garrett
- 5 years ago
- Views:
Transcription
1 Annals of Oncology 21: , 2010 doi: /annonc/mdq039 Published online 18 February 2010 Clinical outcome of leiomyosarcomas of vascular origin: comparison with leiomyosarcomas of other origin A. Italiano 1 *, M. Toulmonde 1, E. Stoeckle 2, M. Kind 3, G. Kantor 4, J.-M. Coindre 5 & B. Bui 1 Departments of 1 Medical Oncology; 2 Surgery; 3 Radiology; 4 Radiotherapy and 5 Pathology, Institut Bergonie, Bordeaux, France. Received 5 November 2009; revised 11 January 2010; accepted 12 January 2010 Background: There are no data about the natural history of leiomyosarcoma of vascular origin (vlms) in comparison with leiomyosarcoma (LMS) of other origin and about the management of advanced disease. Methods: Among 1472 patients diagnosed with sarcoma from January 1980 to December 2008 at our institution, 195 patients (13%) had LMS. LMS had a vascular origin in 14 cases (7%). Results: Patients with vlms had a significantly worse median metastasis-free survival (MFS) (0.25 versus 9.6 years, P = 0.001) and overall survival (OS; 2.1 versus 7 years, P < ) than patients with LMS of other origin. On multivariate analysis, grade and vascular origin were the sole independent adverse prognostic factors for OS. Eight metastatic patients with vlms received a first-line anthracycline chemotherapy regimen. Two patients had partial response, four had stable disease and two had progressive disease. OS of patients with metastatic vlms was not significantly different from that observed in patients with metastatic LMS of other origin (22.1 versus 16.5 months, P = 0.84). Conclusions: Vascular origin is an independent adverse prognostic factor for MFS and OS in patients with LMS. Patients with metastatic vlms had a similar outcome than patients with metastatic LMS of other origin. Key words: chemotherapy, leiomyosarcoma of vascular origin introduction Leiomyosarcomas of vascular origin (vlmss) are extremely rare lesions representing less than one in every malignant tumors [1]. Clinical descriptions are mainly limited to single case reports and only few instances are recorded in several large autopsy series [1]. The sites most frequently involved are large veins such as the vena cava. Pulmonary and systemic arteries locations are exceptional. The prognosis for patients with vlmss is very poor [2 5]. Surgery is the cornerstone of treatment and represents frequently a challenge even for the most experienced surgeons because of disease location. More than 50% of patients with complete macroscopic resection experienced disease recurrence and died of disease progression [2 6]. Moreover, many patients present with locally advanced or metastatic disease at the time of initial diagnosis and are not amenable to surgery. Due to its rarity, no comparison has never been made between vascular and nonvascular soft tissue leiomyosarcomas (LMSs). Moreover, there are no data about the medical management and the role of chemotherapy in patients with advanced vlmss. We report here the first series addressing these specific issues. *Correspondence to: Dr. A. Italiano, Department of Medical Oncology, Institut Bergonié, 229 cours de l Argonne, Bordeaux Cedex, France. Tel: ; Fax: ; italiano@bergonie.org patients and methods patients From 1980 to 2008, 1472 adult patients ( 16 years old) with a diagnosis of soft tissue sarcoma were admitted to our institution (Institut Bergonie, Bordeaux, France). Clinical and pathologic data were collected by reviewing medical records and were entered in a comprehensive database. Among these patients, 195 (13%) had a LMS. LMS had a vascular origin in 14 cases (7%). Histological diagnosis was confirmed for all patients by the same pathologist (J-MC), according to the World Health Organization (WHO) Classification of Tumors [7]. Tumor grade was evaluated according to the Fédération Nationale des Centres de Lutte Contre le Cancer grading system [8, 9]. Variables collected from the medical records included demographic data, tumor characteristics and staging, treatment, patterns of recurrence and followup. Cause of death was coded according to the WHO classification [10]. statistical analyses The statistical analyses of baseline demographics and clinical outcomes were based on all data available up to the cut-off date of 30 April Tumor response was assessed according to RECIST [11]. Overall survival (OS) was defined as the interval between diagnosis and the time of death. Progression-free survival was defined for patients treated with chemotherapy as the interval between initiation of chemotherapy and the time of progression or death from any cause. Univariate and multivariate analyses were carried out using Cox regression and included the following variables: age (<50 or 50 years), sex, tumor size (<5 or 5 cm), tumor site (extremities, internal trunk, head and neck and trunk wall), tumor depth (superficial or deep), grade according to the FNCLCC original article ª The Author Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please journals.permissions@oxfordjournals.org
2 system and vascular origin (yes or no). Variables that were associated with survival with a P value <.05 in the univariate analysis were included in the multivariate regression. Analyses were carried out using SPSS 12.0 statistical software (SPSS Inc., Chicago, IL). All statistical tests were two-sided, and P values <.05 indicated statistical significance. results patients The study population included 195 patients. Their characteristics are summarized in Table 1. Fourteen patients had a vlms Annals of Oncology (Table 2). Tumors arose from veins in 12 cases (86%) and from systemic arteries in only 2 cases (14%). Inferior vena cava was the most frequent tumor location (36%). vlmss tend to be larger ( 5 cm) than LMSs of other origin (93% versus 74%, P = 0.09) and are characterized by a higher rate of synchronous metastases than LMS of other origin (36% versus 15%, P = 0.04). patterns of treatment of patients with vascular LMSs localized setting. At diagnosis, nine vlms patients presented with localized disease (Figures 1 3). Patterns of care and Table 1. Patients characteristics Characteristic All (N = 195) Nonvascular leiomyosarcoma (N = 181) Vascular leiomyosarcoma (N = 14) P value No. of patients % No. of patients % No. of patients % Age, years 0.29 < Sex 0.51 Male Female Size, cm 0.09 < Location 0.06 Superficial Deep Anatomic site 0.42 Extremities Head and neck Trunk wall Internal trunk FNCLCC grade 0.21 Grade Grade Grade Unknown FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer. Table 2. Characteristics of patients with vascular leiomyosarcomas (N = 14) Patient Sex/age Eastern Cooperative Oncology Group Tumor site Tumor size Grade Metastases at diagnosis 1 Female/69 1 Great saphenous vein 10 3 No 2 Male/49 2 Inferior vena cava 10 2 No 3 Male/68 1 Great saphenous vein 10 2 Yes Lung 4 Female/83 1 Great saphenous vein 10 3 No 5 Female/72 1 Femoral vein 7 3 No 6 Female/65 0 Popliteal vein 4 3 No 7 Female/84 3 Common iliac artery 15 3 Yes Lung 8 Male/73 3 Superficial femoral artery 15 3 No _ 9 Male/49 1 Great saphenous vein 9 2 No 10 Male/51 1 Inferior vena cava 6 3 Yes Lung 11 Male/59 1 Inferior vena cava 10 3 Yes Liver 12 Female/69 0 Inferior vena cava 9 2 No 13 Male/58 0 Inferior vena cava 8 3 Yes Liver 14 Male/77 1 Inferior vena cava 8 2 No Metastatic sites at diagnosis 1916 Italiano et al. Volume 21 No. 9 September 2010
3 Annals of Oncology original article Figure 1. Locoregional treatment of nine patients with localized leiomyosarcoma of vascular origin. Figure 2. Chemotherapy in 3 patients with localized leiomyosarcoma of vascular origin. outcome for these patients are detailed in Figure 1. Seven of them underwent resection with a curative intent. Complete gross resection was achieved in all these cases. Two patients (patients 2 and 12) with localized disease at presentation received doxorubicin-based chemotherapy in a neo-adjuvant setting. One of them (case 2) died of cardiac failure before Volume 21 No. 9 September 2010 doi: /annonc/mdq
4 Annals of Oncology Figure 3. Outcome of patients with metastatic leiomyosarcomas of vascular origin treated with chemotherapy. completion of the neo-adjuvant treatment and was not assessed for tumor response. One patient (case 14) was deemed unresectable because of locoregional extension and received palliative chemotherapy. Patients 12 and 14 were assessable for response. The best response according to RECIST criteria was stable disease in both cases. Five out of seven patients with complete resection received postoperative radiotherapy (RT), administered as external beam therapy. The median dose of external beam RT was 45 Gy (range Gy). In one case (case 6), additional brachytherapy by intraoperative seed implantation was carried out. metastatic setting. Ten patients presented with metastatic disease at diagnosis (n = 5) or during the course of their disease (n = 5). The sites of metastases were lung (n = 8), liver (n = 5), skin (n = 3), bone (n = 1) and brain (n = 1). Eight patients received chemotherapy for metastases (Table 3). All of them received an anthracycline-based regimen as first-line therapy Italiano et al. Volume 21 No. 9 September 2010
5 Annals of Oncology Their outcome is summarized in Figure 3. The best response was partial response in two cases, stable disease in four cases and progressive disease in two cases. Six patients received second line chemotherapy and one patient received four lines of chemotherapy. Surgical resection of metastases was carried out in only one patient (case 9). Two patients had not been treated with chemotherapy at the time of analysis because of poor cardiac function (case 4) or low-burden, asymptomatic disease (case 5). OS of patients with metastatic vlms was not significantly different from that observed in patients with metastatic LMS of other origin (median OS: 22.1 versus 16.5 months, P = 0.84). metastasis-free survival original article The median metastasis-free survival (MFS) for the entire cohort of LMS patients was 7.4 years [95% confidence interval (CI) ] (Tables 4 and 5, Figure 4). On univariate analysis, tumor site, tumor size, tumor depth, grade and vascular origin were significantly associated with MFS. On multivariate analysis, grade and vascular origin were the sole independent prognostic factors of MFS. Table 5. Independent prognostic factors on MFS and OS (multivariate analysis) Table 3. Chemotherapy regimens in patients with leiomyosarcoma of vascular origin Protocol Drugs MAID Doxorubicin 20 mg/m 2 (days 1 3) Ifosfamide 2.5 g/m 2 (days 1 3) Dacarbazine 300 mg/m 2 (days 1 3) AD Doxorubicin 20 mg/m 2 (days 1 3) Dacarbazine 300 mg/m 2 (days 1 3) Metronomic etoposide Oral daily etoposide 75 mg/day on 21 of 28-days cycle Metronomic cyclophosphamide Oral daily cyclophosphamide 50 mg/ day on 21 of 28-days cycle Doxorubicin Doxorubicin mg/m 2 Docetaxel gemcitabine Gemcitabine 900 mg/m 2 (days 1 and 8) Docetaxel 100 mg/m 2 (day 8) MAID, mesna, adriamycin, ifosfamide, dacarbazine; AD, adriamycin, dacarbazine. Table 4. Significant prognostic factors on MFS and OS (univariate analysis) Variable Hazard ratio 95% CI P value MFS FNCLCC grade Grade Grade Grade Vascular origin No Yes 1 OS FNCLCC grade Grade Grade Grade 3 1 Size, cm < Vascular origin Yes No 1 CI, confidence interval; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; MFS, metastasis-free survival; OS, overall survival. Variable MFS OS Median MFS (years) 95% CI P value Median OS (years) 95% CI P value Whole population Anatomic Site Extremities (ns) Head and neck NR NR Internal trunk Trunk wall NR FNCLCC grade 1 NR 0.03 NR Location Superficial NR Deep Size, cm <5 NR < Vascular origin Yes < No CI, confidence interval; FNCLCC, Fédération Nationale des Centres de Lutte Contre le Cancer; MFS, metastasis-free survival; NR, median not reached; ns, not significant; OS, overall survival. Volume 21 No. 9 September 2010 doi: /annonc/mdq
6 Annals of Oncology Figure 4. Kaplan Meier curves of metastasis-free (A, C) and overall (B, D) survival of all patients entered into the study (A, B) and according to the vascular origin (C, D). overall survival The median OS for the entire cohort of LMS patients was 5.5 years (95% CI ) (Tables 4 and 5, Figure 4). On univariate analysis, tumor size, tumor depth, grade and vascular origin were significantly associated with OS. In particular, OS of patients with vlms was significantly worse than that of patients with LMS of other origin (median: 2 versus 7 years, P = ). On multivariate analysis, tumor size, grade and vascular origin are the sole independent prognostic factors of OS. discussion LMS is generally recognized as an aggressive disease with a generally poor prognosis compared with other soft tissue sarcomas. Only one study has compared the prognosis of vlms with LMS of other anatomic sites [12]. The authors reported similar prognosis in localized LMS of different origin. However, this study included only patients with LMS of the vena cava. Moreover, the comparison was not made with other soft tissue LMSs but mainly with a small series of selected cases of visceral LMS (stomach: n = 13, small intestine: n = 18 and uterus: n = 10). All these cases were diagnosed between October 1972 and November 1996, e.g. before the discovery of KIT mutations in stromal gastrointestinal tumors (GIST) and were not submitted to a central histological review [13]. Therefore, we believe that the gastric and intestinal LMSs included in this series were not true LMSs but GIST. Indeed, most tumors referred to as gastrointestinal leiomyomas and LMSs in the older medical literature are actually GISTs [14]. This may explain the similar or better outcome of LMS of the vena cava in comparison with the other cases included in this series Italiano et al. Volume 21 No. 9 September 2010
7 Annals of Oncology Our study identified vascular origin as an independent adverse prognostic factor for MFS and OS in patients with softtissue LMSs. In our experience, vlmss account for <2% of soft tissue sarcomas with the inferior vena cava representing the predominant location. In the context of localized disease, complete surgical resection of the vessel segment is the treatment of choice. However, surgery remains a challenge due to the location of the tumor. In our series, only eight patients (57%) had potentially resectable disease at diagnosis. This proportion is consistent with that of previous reports [6]. Due to its rarity, the role of neo-adjuvant chemotherapy and RT in the management of this rare disease is still unknown. RT has been indicated to improve outcome of patients with LMS of inferior vena cava [12]. In our small series, only one patient had local recurrence 27 months after the initial diagnosis. Of the five patients in our series who received adjuvant RT after resection of their primary tumor, one developed a local recurrence and four developed distant metastases. Of the two patients who did not receive adjuvant RT, one developed distant metastases without evidence of local recurrence and one remain disease free at last follow-up. In the series of Ito et al. [15], the rate of local recurrence was not significantly different between patients who received perioperative RT and those who did not. Of the eight patients who received perioperative RT, one developed a local recurrence, five developed distant metastases and two remained disease free at last follow-up. Altogether, such data indicate only a limited role of RT in the management of vlms which are essentially characterized by a metastatic risk. In our series, this metastatic risk is significantly higher than that observed for LMS of other origin. This difference remained significant even after exclusion in the second group of the superficial tumors, which are mainly cutaneous LMSs (data not shown). Several hypotheses may explain the higher metastatic potential of vlms. Obviously, the location of vlms favors hematogeneous spread. Intrinsic biological difference between vlms and LMS of other origin is possible but not likely. For instance, the proportion of patients with intermediate-grade (grade 2) and high-grade (grade 3) disease was similar between the two groups. Moreover, the survival of patients with metastatic disease was very similar, whatever the origin of the primary tumor. Another explanation of the high metastatic potential of vlms is related to a possible delay in diagnosis particularly for those originating form the inferior vena cava. This may explain the higher proportion of lesions 5 cm (93% versus 74%, P = 0.09) and the higher rate of synchronous metastases (36% versus 15%, P = 0.04) in the group of vlms even if theses difference were only marginally significant. There are no data in the literature about the outcome of patients with metastatic vlms. In our study, the objective response rate of vlms patients treated with first-line anthracycline-based chemotherapy was not different from the results reported by previous studies including patients with LMS of other sites [16, 17]. Moreover, our results demonstrated that the survival of patients with metastatic vlms was not different from that observed in patients with LMS of other sites. In our series, the two patients with metastatic LMS originating from peripheral arteria had the worst outcome. These data confirm that arterial LMSs tend to behave more aggressively than their venous counterparts as suggested by previous authors [18]. In conclusion, our study demonstrates that vascular origin is an independent adverse prognostic factor for MFS and OS in patients with LMS. For patients with advanced disease, standard medical management including first-line anthracycline-containing regimen produces survival results that are similar to those observed with other subtypes of LMSs. references original article 1. Enzinger F, Weiss S. Soft Tissue Tumors. St Louis: Mosby Kevorkian J, Cento DP. Leiomyosarcoma of large arteries and veins. Surgery 1973; 73: Stringer BD. Leiomyosarcoma of artery and vein. Am J Surg 1977; 134: Dzsinich C, Gloviczki P, van Heerden JA et al. Primary venous leiomyosarcoma: a rare but lethal disease. J Vasc Surg 1992; 15: Sakpal SV, Mehta R, Babel N, Chamberlain RS. Peripheral artery leiomyosarcoma. J Vasc Surg 2009; 49: Mingoli A, Cavallaro A, Sapienza P et al. International registry of inferior vena cava leiomyosarcoma: analysis of a world series on 218 patients. Anticancer Res. 1996; 16: Fletcher C, Unni K, Mertens F (eds). World Health Organization Classification of Tumours Pathology and Genetics of Tumours of Soft Tissue and Bone. 2002; IARC Press, Lyon. 8. Trojani M, Contesso G, Coindre JM et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: Guillou L, Coindre JM, Bonichon F et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15: World Health Organization. International Classification of Diseases, 1965 Revision. Geneva, Switzerland: World Health Organization Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: Hines OJ, Nelson S, Quinones-Baldrich WJ, Eilber FR. Leiomyosarcoma of the inferior vena cava: prognosis and comparison with leiomyosarcoma of other anatomic sites. Cancer 1999; 85: Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: Miettinen M, Lasota J. Gastrointestinal stromal tumors definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001; 438: Ito H, Hornick JL, Bertagnolli MM et al. Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol 2007; 14: Van Glabbeke M, van Oosterom AT, Oosterhuis JW et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: Penel N, Italiano A, Isambert N et al. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy. Ann Oncol Oct 30. [Epub ahead of print] doi: /annonc/mdp Penel N, Taieb S, Ceugnart L et al. Report of eight recent cases of locally advanced primary pulmonary artery sarcomas: failure of Doxorubicin-based chemotherapy. J Thorac Oncol 2008; 3: Volume 21 No. 9 September 2010 doi: /annonc/mdq
Prognostic Factors and Impact of Adjuvant Treatments on Local and Metastatic Relapse of Soft-Tissue Sarcoma Patients in the Competing Risks Setting
Prognostic Factors and Impact of Adjuvant Treatments on Local and Metastatic Relapse of Soft-Tissue Sarcoma Patients in the Competing Risks Setting Antoine Italiano, MD, PhD 1 ; Axel Le Cesne, MD 2 ; Jean
More informationTrends in Survival for Patients With Metastatic Soft-Tissue Sarcoma
Trends in Survival for Patients With Metastatic Soft-Tissue Sarcoma Antoine Italiano, MD, PhD 1 ; Simone Mathoulin-Pelissier, MD, PhD 2,3 ; Axel Le Cesne, MD 4 ; Philippe Terrier, MD 5 ; Sylvie Bonvalot,
More informationLeiomyosarcoma: One Disease or Distinct Biologic Entities Based on Site of Origin?
2015;111:808 812 Leiomyosarcoma: One Disease or Distinct Biologic Entities Based on Site of Origin? DAVID J. WORHUNSKY, MD, 1 MIHIR GUPTA, BS, 1 SEPIDEH GHOLAMI, MD, 1 THUY B. TRAN, MD, 1 KRISTEN N. GANJOO,
More informationLeiomyosarcoma of the inferior vena cava: 1 case. B. Bancel, A. Rode, C. Ducerf. Hôpital CROIX ROUSSE LYON. Case report
Leiomyosarcoma of the inferior vena cava: 1 case B. Bancel, A. Rode, C. Ducerf Hôpital CROIX ROUSSE LYON Bucharest Nov 2011 Case report 34 yr-old woman, no antecedent Sept 2004: Abdominal upper right quadrant
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationPan Arab Journal of Oncology
Pan Arab Journal of Oncology Original Article Retrospective Analysis of Clinicopathologic and Management Aspects of Soft Tissue Sarcoma Tarek Hussein Kamel, Azza Mohamed Adel, Reham Mohamed Faheim, Rana
More informationSurgical outcome and patterns of recurrence for retroperitoneal sarcoma at a single centre
ONCOLOGY Ann R Coll Surg Engl 2016; 98: 192 197 doi 10.1308/rcsann.2016.0057 Surgical outcome and patterns of recurrence for retroperitoneal sarcoma at a single centre HDJ Hogg 1, DM Manas 1, D Lee 1,
More informationA Korean single center, real world, retrospective study of first line weekly paclitaxel in patients with metastatic angiosarcoma
DOI 10.1186/s13569-016-0048-0 Clinical Sarcoma Research RESEARCH Open Access A Korean single center, real world, retrospective study of first line weekly paclitaxel in patients with metastatic angiosarcoma
More informationPrognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk
843 Prognostic Significance of Grading and Staging Systems using MIB-1 Score in Adult Patients with Soft Tissue Sarcoma of the Extremities and Trunk Tadashi Hasegawa, M.D. 1 Seiichiro Yamamoto, Ph.D. 2
More informationIntroduction ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access The effect of radiation therapy in the treatment of adult soft tissue sarcomas of the extremities: a long- term community- based cancer center experience Jeffrey
More informationResearch Article Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin
Sarcoma Volume 2009, Article ID 348910, 6 pages doi:10.1155/2009/348910 Research Article Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine
More informationAll India Institute of Medical Sciences, New Delhi, INDIA. Department of Pediatric Surgery, Medical Oncology, and Radiology
All India Institute of Medical Sciences, New Delhi, INDIA Department of Pediatric Surgery, Medical Oncology, and Radiology Clear cell sarcoma of the kidney- rare renal neoplasm second most common renal
More informationsarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.
1994, The British Journal of Radiology, 67, 129-135 Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER,
More informationScandinavian Sarcoma Group. Ass. Prof. Otte Brosjö,, Karolinska Hospital, Stockholm
Scandinavian Sarcoma Group Ass. Prof. Otte Brosjö,, Karolinska Hospital, Stockholm The Scandinavian Sarcoma Group Organisation of Care and Research Quality management - the SSG experience Multidisciplinary
More informationPrognostic factors in adult soft tissue sarcoma treated with surgery combined with radiotherapy: a retrospective single-center study on 164 patients
Rare Tumors 2013; volume 5:e55 Prognostic factors in adult soft tissue sarcoma treated with surgery combined with radiotherapy: a retrospective single-center study on 164 patients Ling Cai, 1 René-Olivier
More informationClinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma
ISRN Dermatology Volume 2013, Article ID 586915, 5 pages http://dx.doi.org/10.1155/2013/586915 Clinical Study Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationoriginal article introduction original article
Annals of Oncology 00: 1 6, 2014 doi:10.1093/annonc/mdt576 Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis
More informationSynovial Sarcoma of Extremities: Evaluation of Prognostic Factors and Clinical Outcomes
Med. J. Cairo Univ., Vol. 81, No. 1, December: 1093-1097, 2013 www.medicaljournalofcairouniversity.net Synovial Sarcoma of Extremities: Evaluation of Prognostic Factors and Clinical Outcomes SEHAM E. ABDELKHALEK,
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 April 2008 YONDELIS 0.25 mg, vial containing powder for concentrate for solution for infusion Box containing 1 vial
More informationRetroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients
Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients INGO ALLDINGER 1,2, QIN YANG 3, CHRISTIAN PILARSKY 1, HANS-DETLEV SAEGER 1, WOLFRAM T. KNOEFEL
More informationA rare case of rapidly progressing angiosarcoma of the breast with multiple metastases to the bone, liver, ovary, and gingiva
Int Canc Conf J (2012) 1:159 163 DOI 10.1007/s13691-012-0032-3 CASE REPORT A rare case of rapidly progressing angiosarcoma of the breast with multiple metastases to the bone, liver, ovary, and gingiva
More informationSummary... 2 SARCOMA Neoadjuvant chemotherapy in patients with localised high-risk STS... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 SARCOMA... 3 Neoadjuvant chemotherapy in patients with localised high-risk STS... 3 No additional benefit with evofosfamide
More informationMultidisciplinary management of retroperitoneal sarcomas
Multidisciplinary management of retroperitoneal sarcomas Eric K. Nakakura, MD UCSF Department of Surgery UCSF Comprehensive Cancer Center San Francisco, CA 7 th Annual Clinical Cancer Update North Lake
More informationSoft Tissue Sarcoma. Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee
Soft Tissue Sarcoma Presley Regional Trauma Center Department of Surgery University of Tennessee Health Science Center Memphis, Tennessee Soft Tissue Sarcoma Collective term for an unusual and diverse
More informationJose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma
Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre Evolution of liver resection Better understanding
More informationSoft-tissue sarcomas in the head and neck: 25 years of experience
Soft-tissue sarcomas in the head and neck: 25 years of experience Juan Francisco Liuzzi 1, Maribel Da Cunha 2, Daniuska Salas 2, Saul Siso 2 and Esteban Garriga 2 1 Head and Neck Department, Hospital Oncology
More informationORIGINAL ARTICLE. Adult Soft Tissue Ewing Sarcoma or Primitive Neuroectodermal Tumors
Adult Soft Tissue Ewing Sarcoma or Primitive Neuroectodermal Tumors Predictors of Survival? Robert C. G. Martin II, MD; Murray F. Brennan, MD ORIGINAL ARTICLE Background: Ewing sarcoma (ES) is the second
More informationAuthor's response to reviews
Author's response to reviews Title: Should tumor depth be included in prognostication of soft tissue sarcoma? Minor prognostic value of tumor depth in a population-based series of 490 patients with soft
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdominal drainage, after hepatic resection, 159 160 Ablation, radiofrequency, for hepatocellular carcinoma, 160 161 Adenocarcinoma, pancreatic.
More informationPrinted by Maria Chen on 3/11/2012 5:46:52 AM. For personal use only. Not approved for distribution. Copyright 2012 National Comprehensive Cancer
, Table of Contents NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level
More informationLeiomyosarcoma involving the inferior vena cava in an. elderly patient with reference to its operative modalities: a case report
Leiomyosarcoma involving the inferior vena cava in an elderly patient with reference to its operative modalities: a case report Hiroshi Ushida 1, Ryosuke Murai 1, Mitsuhiro Narita 1, Fumiyoshi Kojima 2
More informationClinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter
Hindawi Publishing Corporation Journal of Oncology Volume 2008, Article ID 212067, 5 pages doi:10.1155/2008/212067 Clinical Study Small Bowel Tumors: Clinical Presentation, Prognosis, and Outcomein33PatientsinaTertiaryCareCenter
More informationThe management of myxofibrosarcoma a ten-year experience in a single specialist centre
Acta Orthop. Belg., 2014, 80, 436-441 ORIGINAL STUDY The management of myxofibrosarcoma a ten-year experience in a single specialist centre Jessica Daniels, Carl M. Green, Anthony Freemont, Ashok Paul
More informationSurgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database
Surgical Management of Metastatic Colon Cancer: analysis of the Surveillance, Epidemiology and End Results (SEER) database Hadi Khan, MD 1, Adam J. Olszewski, MD 2 and Ponnandai S. Somasundar, MD 1 1 Department
More informationORIGINAL ARTICLE. Clinical Node-Negative Thick Melanoma
ORIGINAL ARTICLE Clinical Node-Negative Thick Melanoma George I. Salti, MD; Ashwin Kansagra, MD; Michael A. Warso, MD; Salve G. Ronan, MD ; Tapas K. Das Gupta, MD, PhD, DSc Background: Patients with T4
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationLong Term Results in GIST Treatment
Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal
More informationLocoregional treatment Session Oral Abstract Presentation Saulo Brito Silva
Locoregional treatment Session Oral Abstract Presentation Saulo Brito Silva Background Post-operative radiotherapy (PORT) improves disease free and overall suvivallin selected patients with breast cancer
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 YONDELIS 0.25 mg, powder for concentrate for solution for infusion Box of 1 vial (CIP: 571 522-9) YONDELIS
More informationCase Presentation. Gordon Callender M.D. Surgical Resident
Case Presentation Gordon Callender M.D. Surgical Resident Retroperitoneal Sarcomas Sarcomas Heterogeneous group of rare tumors that arise predominantly from the embryonic mesoderm. Expected incidence for
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationRole of Primary Resection for Patients with Oligometastatic Disease
GBCC 2018, April 6, Songdo ConvensiA, Incheon, Korea Panel Discussion 4, How Can We Better Treat Patients with Metastatic Disease? Role of Primary Resection for Patients with Oligometastatic Disease Tadahiko
More informationUpdate on Sarcomas of the Head and Neck. Kevin Harrington
Update on Sarcomas of the Head and Neck Kevin Harrington Overview Classification and incidence of sarcomas Clinical presentation Challenges to treatment Management approaches Prognostic factors Radiation-induced
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationCON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer
CON: Removal of the Breast Primary in Patients with Metastatic Breast Cancer Amelia B. Zelnak, M.D., M.Sc. Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute Emory University
More informationManaging adult soft tissue sarcomas and gastrointestinal stromal tumours
Managing adult soft tissue sarcomas and gastrointestinal stromal tumours Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo
More informationProtocol for the Examination of Specimens From Patients With Primary Malignant Tumors of the Heart
Protocol for the Examination of Specimens From Patients With Primary Malignant Tumors of the Heart Protocol applies to primary malignant cardiac tumors. Hematolymphoid neoplasms are not included. No AJCC/UICC
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationWhen is local surgery indicated in metastatic breast cancer?
When is local surgery indicated in metastatic breast cancer? NICOLA ROCHE THE ROYAL MARSDEN HOSPITAL IBCS 2018 Stage at diagnosis 2014 Survival with Stage IV breast cancer Hypothesis Surgical removal of
More informationTreatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy
Korean J Hepatobiliary Pancreat Surg 2011;15:152-156 Original Article Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy Suzy Kim 1,#, Kyubo
More informationRadiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience
Radiotherapy and Conservative Surgery For Merkel Cell Carcinoma - The British Columbia Cancer Agency Experience Poster No.: RO-0003 Congress: RANZCR FRO 2012 Type: Scientific Exhibit Authors: C. Harrington,
More informationReference No: Author(s) NICaN Drugs and Therapeutics Committee. Approval date: 12/05/16. January Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Gastro- Intestinal Stromal Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationRetroperitoneal liposarcoma: the role of adjuvant radiation therapy and the prognostic factors
Original Article Radiat Oncol J 216;34(3):216222 http://dx.doi.org/1.3857/roj.216.1858 pissn 223419 eissn 22343156 Retroperitoneal liposarcoma: the role of adjuvant radiation therapy and the prognostic
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationOncologist. The. Sarcomas. Primary Malignant Sarcomas of the Heart and Great Vessels in Adult Patients A Single-Center Experience
The Oncologist Sarcomas Primary Malignant Sarcomas of the Heart and Great Vessels in Adult Patients A Single-Center Experience FRANK MAYER, a HERMANN AEBERT, b,g MAXIMILIAN RUDERT, c,g ALFRED KÖNIGSRAINER,
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 22 NOVEMBER 15 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Cohort Analysis of Patients With Localized, High-Risk, Extremity Soft Tissue Sarcoma Treated at Two Cancer
More informationChapter 2 Natural History: Importance of Size, Site, and Histopathology
Chapter 2 Natural History: Importance of Size, Site, and Histopathology Natural History The natural history of soft tissue sarcoma is highly in fl uenced by the site of the primary lesion, tumor histopathology,
More informationXiang Hu*, Liang Cao*, Yi Yu. Introduction
Original Article Prognostic prediction in gastric cancer patients without serosal invasion: comparative study between UICC 7 th edition and JCGS 13 th edition N-classification systems Xiang Hu*, Liang
More information290 Clin Oncol Cancer Res (2009) 6: DOI /s
290 Clin Oncol Cancer Res (2009) 6: 290-295 DOI 10.1007/s11805-009-0290-9 Analysis of Prognostic Factors of Esophageal and Gastric Cardiac Carcinoma Patients after Radical Surgery Using Cox Proportional
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationEFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA
ORIGINAL ARTICLE EFFICACY OF NECK DISSECTION FOR LOCOREGIONAL FAILURES VERSUS ISOLATED NODAL FAILURES IN NASOPHARYNGEAL CARCINOMA Raymond King Yin Tsang, FRCSEd, Joseph Chun Kit Chung, MRCSEd, Yiu Wing
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/55957 holds various files of this Leiden University dissertation Author: Dekker T.J.A. Title: Optimizing breast cancer survival models based on conventional
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationResearch Article Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma
Sarcoma Volume 2015, Article ID 532478, 7 pages http://dx.doi.org/10.1155/2015/532478 Research Article Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma Mark A. Dickson,
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationMANAGEMENT OF COLORECTAL METASTASES. Robert Warren, MD. The Postgraduate Course in General Surgery March 22, /22/2011
MANAGEMENT OF COLORECTAL METASTASES Robert Warren, MD The Postgraduate Course in General Surgery March 22, 2011 Local Systemic LIVER TUMORS:THERAPEUTIC OPTIONS Hepatoma Cholangio. Neuroendo. Colorectal
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationCase Report Primary Diaphragmatic Dedifferentiated Liposarcoma in a Young Female Patient after Delivery
Case Reports in Oncological Medicine Volume 2016, Article ID 4042719, 4 pages http://dx.doi.org/10.1155/2016/4042719 Case Report Primary Diaphragmatic Dedifferentiated Liposarcoma in a Young Female Patient
More informationClinical analysis of 29 cases of nasal mucosal malignant melanoma
1166 Clinical analysis of 29 cases of nasal mucosal malignant melanoma HUANXIN YU and GANG LIU Department of Otorhinolaryngology Head and Neck Surgery, Tianjin Huanhu Hospital, Tianjin 300060, P.R. China
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationBone HDR brachytherapy in a patient with recurrent Ewing s sarcoma of the acetabulum: Alternative to aggressive surgery
Bone HDR brachytherapy in a patient with recurrent Ewing s sarcoma of the acetabulum: Alternative to aggressive surgery Rafael Martínez-Monge 1,* Agata Pérez-Ochoa 1, Mikel San Julián 2, Dámaso Aquerreta
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationAge group No. of patients >60 15 Total 108
88 Original Article Soft Tissue Sarcoma in Uganda. A.M. Gakwaya 1, J. Jombwe 2, 1 Senior Consultant Surgeon, 2 Senior registrar, Dept. Of Surgery Mulago Hospital Complex, Kampala, Uganda Correspondence
More informationUnusual Osteoblastic Secondary Lesion as Predominant Metastatic Disease Spread in Two Cases of Uterine Leiomyosarcoma
49 Unusual Osteoblastic Secondary Lesion as Predominant Metastatic Disease Spread in Two Cases of Uterine Leiomyosarcoma Loredana Miglietta a Maria Angela Parodi b Luciano Canobbio b Luca Anselmi c a Medical
More informationTreatment and prognosis of type B2 thymoma
Song et al. World Journal of Surgical Oncology 2014, 12:291 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access Treatment and prognosis of type B2 thymoma Zhengbo Song 1,2, Xiangyu Jin 1,2 and Yiping
More informationIrinotecan and temozolomide in adults with recurrent sarcoma
ORIGINAL ARTICLE Irinotecan and temozolomide in adults with recurrent sarcoma Phillip S. Blanchette 1, Aaron Lo 2, Pamela Ng 2, Albiruni Razak 3,4, Eitan Amir 4, David Hogg 4, Martin E. Blackstein 3, Abha
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationSYNOPSIS PROTOCOL N UC-0107/1602
SYNOPSIS PROTOCOL N UC-0107/1602 A) TRIAL IDENTIFICATION SPONSOR PROTOCOL CODE NUMBER: UC-0107/1602 VERSION (NR & DATE): 0.1, MARCH 2016 TRIAL TITLE: Extracranial Stereotactic Body Radiation Therapy (SBRT)
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationSPAEN Meeting: Desmoid Tumors
SPAEN Meeting: Desmoid Tumors 23 rd of November 2012, Firenze, Italy Update on systemic treatment options and clinical trials in desmoids Bernd Kasper University of Heidelberg Mannheim University Medical
More informationPoor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas
10 The Open Otorhinolaryngology Journal, 2011, 5, 10-14 Open Access Poor Outcomes in Head and Neck Non-Melanoma Cutaneous Carcinomas Kevin C. Huoh and Steven J. Wang * Head and Neck Surgery and Oncology,
More informationGuidelines for the management of soft tissue sarcomas. The British Sarcoma Group Authors:
Guidelines for the management of soft tissue sarcomas. The British Sarcoma Group Authors: Mr Robert Grimer Consultant Orthopaedic Surgeon, Royal Orthopaedic Hospital, Birmingham Prof Ian Judson Consultant
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationMauricio Camus Appuhn Associate Professor Chief, Department of Surgical Oncology, Pontificia Universidad Católica de Chile
May 18-20, 2017 18 a 20 de Maio / 2017 Castro's Park Hotel Surgery for metastatic breast cancer: the controversy of local surgery for metastatic breast cancer Cirurgia em câncer de mama metastático: a
More informationAnalysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors
Ann Surg Oncol DOI 10.1245/s10434-014-3632-7 ORIGINAL ARTICLE BONE AND SOFT TISSUE SARCOMAS Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy
More informationOriginal Article. Keywords: Gastrointestinal stromal tumors (GIST); KIT; tyrosine kinase inhibitors (TKIs); immunohistochemical staining
Original Article Treatment of non-resectable and metastatic gastrointestinal stromal tumors: experience with the use of tyrosine kinase inhibitors in a third level hospital in Mexico Abdel Karim Dip Borunda,
More informationPathologic Characteristics of Resected Squamous Cell Carcinoma of the Trachea: Prognostic Factors Based on an Analysis of 59 Cases
Pathologic Characteristics of Resected Squamous Cell Carcinoma of the Trachea: Prognostic Factors Based on an Analysis of 59 Cases The Harvard community has made this article openly available. Please share
More informationANTICANCER RESEARCH 28: (2008)
Comparative Analysis of Four Histopathological Classification Systems to Discriminate Benign and Malignant Behaviour in Gastrointestinal Stromal Tumors D. VALLBÖHMER 1, H.E. MARCUS 1, S.E. BALDUS 2, J.
More informationThe other bone sarcomas
ONCOLOGY The other bone sarcomas PROGNOSTIC FACTORS AND OUTCOMES OF SPINDLE CELL SARCOMAS OF BONE E. E. Pakos, R. J. Grimer, D. Peake, D. Spooner, S. R. Carter, R. M. Tillman, S. Abudu, L. Jeys From Royal
More information